Dual-Functioning Metal-Organic Frameworks: Methotrexate-Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers

Basit Öğe Kaydı
dc.authorid0000-0003-4750-3628
dc.authorid0000-0003-0717-7637
dc.authorid0000-0002-4851-3062
dc.authorid0000-0002-7781-3355
dc.authorid0000-0001-6401-686X
dc.contributor.authorKaraca, Burcu
dc.contributor.authorSakarya, Deniz
dc.contributor.authorSiyah, Pinar
dc.contributor.authorSenisik, Ahmet M.
dc.contributor.authorKaptan, Yasemin
dc.contributor.authorCavusoglu, Ferda C.
dc.contributor.authorMansuroglu, Demet S.
dc.date.accessioned2026-01-31T15:08:08Z
dc.date.available2026-01-31T15:08:08Z
dc.date.issued2025
dc.departmentİstanbul Beykent Üniversitesi
dc.description.abstractCancer remains a critical global health challenge, necessitating advanced drug delivery systems through innovations in materials science and nanotechnology. This study evaluates gadolinium metal-organic frameworks (Gd-MOFs) as potential drug delivery systems for anticancer therapy, particularly when combined with radiotherapy. Gd-MOFs were synthesized using terephthalic acid and gadolinium (III) chloride hexahydrate and then loaded with methotrexate (MTX). Characterization via fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), magnetic resonance imaging (MRI), and X-ray diffraction (XRD) confirmed their correct structure and stability. Effective MTX loading and controlled release were demonstrated. Anticancer effects were assessed on human healthy bronchial epithelial cells (BEAS-2B) and human lung cancer cells (A549) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay under in vitro radiation therapy. MTX/Gd-MOF combined with radiotherapy showed a greater reduction in cancer cell viability (41.89% +/- 2.75 for A549) compared to healthy cells (56.80% +/- 1.97 for BEAS-2B), indicating selective cytotoxicity. These findings highlight the potential of Gd-MOFs not only as drug delivery vehicles but also as radiosensitizers, enhancing radiotherapy efficacy and offering promising evidence for their use in combinatory cancer therapies to improve treatment outcomes.
dc.description.sponsorshipTÜBİTAK ULAKBİM (Istanbul University-Cerrahpasa) Funding Source: Medline
dc.identifier.doi10.1002/chem.202404106
dc.identifier.issn0947-6539
dc.identifier.issn1521-3765
dc.identifier.issue24
dc.identifier.pmid40079794
dc.identifier.scopus2-s2.0-105003823363
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org./10.1002/chem.202404106
dc.identifier.urihttps://hdl.handle.net/20.500.12662/10591
dc.identifier.volume31
dc.identifier.wosWOS:001479486400014
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofChemistry-A European Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260128
dc.subjectcontrolled drug release
dc.subjectGd-MOF
dc.subjectmethotrexate
dc.subjectMRI
dc.subjectradiotherapy
dc.titleDual-Functioning Metal-Organic Frameworks: Methotrexate-Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu